- Datum28.10.2025
- Uhrzeit18:00 - 19:00 Uhr
- Veranstalter
stock3
Ingmar Königshofen
Moderator
CureVac N.V. Namensaktien o.N. Aktie
Verkaufen
Kaufen
CureVac N.V. Namensaktien o.N. Chart
Charts analysieren
wie die Profis?
Nutze unser Profi-Charting-Tool für Deine eigenen Analysen
Chart analysieren
CureVac N.V. Namensaktien o.N. Realtime-Kurs
| Handelsplatz | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
|---|---|---|---|---|---|---|
| L&S | VK | |||||
| Tradegate | VK | |||||
| Stuttgart | VK |
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Keine Ergebnisse gefunden
Wertentwicklung (Nasdaq)
0,37 %
Intraday
0,19 %
1 Woche
0,19 %
1 Monat
57,77 %
Seit Jahresbeginn
90,11 %
1 Jahr
-29,21 %
3 Jahre
-88,46 %
5 Jahre
Passender Service zu CureVac N.V. Namensaktien o.N.
Webinar zu CureVac N.V. Namensaktien o.N.
Kursinformationen (Nasdaq)
- Tagestief / Hoch ($)-
- 52W-Tief / Hoch ($)2,370-5,720
- Jahrestief / Hoch ($)---
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von CureVac N.V. Namensaktien o.N.
Keine Dividenden verfügbar
Termine von CureVac N.V. Namensaktien o.N.
- Nov18CureVac N.V. Namensaktien o.N.Q3 2025 Earnings Release
- Apr29CureVac N.V. Namensaktien o.N.Q4 2025 Earnings Release
- Mai27CureVac N.V. Namensaktien o.N.Q1 2026 Earnings Release
Beschreibung
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. The company was founded in 2000 and is headquartered in Tübingen, Germany.
